Skip to main navigation
Skip to search
Skip to main content
UT MD Anderson Cancer Center Home
Help & FAQ
Link opens in a new tab
Search content at UT MD Anderson Cancer Center
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
New chemotherapeutic agents in acute myeloid leukemia
H. M. Kantarjian
, E. H. Estey
, M. A. Keating
Leukemia
Research output
:
Contribution to journal
›
Article
›
peer-review
36
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'New chemotherapeutic agents in acute myeloid leukemia'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acute Myeloid Leukemia
100%
Ara-C
80%
Complete Response Rate
60%
Salvage Therapy
60%
Nucleoside Analogues
40%
Decitabine
40%
Topo I Inhibition
40%
Combination Therapy
20%
Survival Rate
20%
Mechanism of Action
20%
New Agents
20%
Topotecan
20%
Anthracyclines
20%
Biological Agents
20%
Fludarabine
20%
Topoisomerase II
20%
Event-free Survival
20%
Newly Diagnosed Patients
20%
Homoharringtonine
20%
Hypomethylating Agents
20%
VP16
20%
5-azacytidine
20%
Platinum Agents
20%
Novel Mechanism of Action
20%
Differentiating Agents
20%
Platinum Analogs
20%
Reactive Agent
20%
Agent Efficacy
20%
Long-term Events
20%
2-CdA
20%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Cytarabine
80%
Nucleoside Analog
40%
Decitabine
40%
Cladribine
20%
Combination Therapy
20%
Survival Rate
20%
Anthracycline
20%
Topotecan
20%
Etoposide
20%
Fludarabine
20%
DNA Topoisomerase (ATP Hydrolysing)
20%
Omacetaxine Mepesuccinate
20%
Event Free Survival
20%
Azacitidine
20%
Platinum Derivative
20%
Tallimustine
20%